<DOC>
	<DOCNO>NCT00908752</DOCNO>
	<brief_summary>The purpose study compare Overall Survival ( OS ) HCC patient receive brivanib adjuvant treatment TACE therapy , OS HCC patient receive match placebo TACE therapy .</brief_summary>
	<brief_title>Phase III Trans-Arterial Chemo-Embolization ( TACE ) Adjuvant HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Patients diagnosis hepatocellular carcinoma Cirrhotic status ChildPugh Class A B score 7 ECOG performance status 0 1 Adequate hematologic , hepatic , renal function Exclusion criterion : Prior use systemic anticancer chemotherapy , immunotherapy , investigational molecular target agent HCC History cardiac disease Active untreated hepatitis B Inability swallow tablet untreated malabsorption syndrome History human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HCC</keyword>
</DOC>